(2)
- Earlier test hole CK20-04cA, which was lost at 29.6m (97 ft) and averages 29.2 meters of 5.075 g/t AuEq, shows similar grades and mineralization thicknesses as CK20-04cB.
- 04cB also includes an interval of 104 meters (342 ft) of 1.41 g/t AuEq below the higher-grade intercept.
- Drill hole location was to obtain metallurgical sample for process optimization from the center of the deposit as outlined by historical drilling, 380 ft east from CK20-01c, released December 16, 2020.
ELKO, Nevada, Dec. 29, 2020 /PRNewswire/ U.S. Gold Corp. (NASDAQ: USAU) (the Company ), a gold exploration and development company, is pleased to announce additional results of the recent twenty-nine hole drilling program for its CK Gold Project, an advanced stage gold and copper exploration and development project located just outside of Cheyenne, Wyoming.
SAP acquired Qualtrics back in January 2019 for $8 billion thus halting the intended IPO.
Cloud-based subscription software platform Qualtrics International Inc has filed for an IPO with the United States Securities and Exchange Commission (SEC) after two years under SAP SE (NYSE: SAP). According to its IPO prospectus, Qualtrics has set the initial price range between $20 and $24. Hereby anticipating to raise its valuation from $8 billion to between $12 and $14 billion.
Notably, Qualtrics will trade on the Nasdaq exchange under the ticker “XM.” SAP acquired Qualtrics back in January 2019 for $8 billion thus halting the intended IPO. Apparently, Qualtrics intended to raise gross proceeds of $200 million through an initial public offering (IPO) of its Class B shares, hence making the acquisition attractive.
bitcoin closes historic year targeting $ 30,000 explica.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from explica.co Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in .
Myovant Sciences, Inc.December 28, 2020 GMT
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™
(relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada
Myovant to receive an upfront payment of $650 million in addition to potential regulatory and sales milestones for a total payment of up to $4.2 billion
Myovant to host conference call and webcast today at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time
BASEL, Switzerland and NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced a collaboration to develop and commercialize relugolix – a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist – in oncology and women’s health in the U.S. and Canada
不甩疫情，盤點 2020 年五大最強投資，到底在漲什麼？ technews.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from technews.tw Daily Mail and Mail on Sunday newspapers.